New drug cuts down genetically inherited heart disease risk factor
“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...
Genetic Heart Disease: Can this investigational drug treat the incurable?
Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition ...
AHA/ASA Journals3d
Return to Play With Genetic Heart Disease: The Importance of Developing a Personalized Emergency Action Plan
Shared decision-making forms an increasingly important part of the expert consultation for athletes with genetic heart ...
An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
Cardiologist and patient advocate spotlight genetic risk of heart disease
This segment is sponsored by Family Heart Foundation.Heart disease remains the leading cause of death in America, but few ...
MPR3d
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Medscape13d
FDA Expands Vutrisiran Indication to ATTR-Cardiomyopathy
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...